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MEETING REPORT Open Access
Dry computational approaches for wet
medical problems
Frank Emmert-Streib1*, Shu-Dong Zhang2 and Peter Hamilton2
Abstract
This is a report on the 4th international conference in ‘Quantitative Biology and Bioinformatics in Modern Medicine’
held in Belfast (UK), 19–20 September 2013. The aim of the conference was to bring together leading experts from a
variety of different areas that are key for Systems Medicine to exchange novel findings and promote interdisciplinary
ideas and collaborations.
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Introduction
Breathtaking technological progress fueled by the human
genome project [1] enables nowadays a quantitative,
data-driven approach to study, not only basic biologi-
cal processes, but also biomedical and clinical questions.
For this reason, computational statistics approaches are
needed for analyzing, integrating and interpreting high-
throughput genomics data.
The 4th international conference in ‘Quantitative Biol-
ogy and Bioinformatics in Modern Medicine’ aimed to
foster quantitative research in Translational Bioinfor-
matics comprising Computational Biology, Biomedical
Informatics, Systems Biology andNetworkMedicine, with
particular focus on disease-related problems and espe-
cially cancer. Due to the interdisciplinary character of the
subject the invited speakers came fromMedicine, Clinical
Sciences, Biology and Computational Biology to provide
a balanced overview of different aspects of the ‘same’
underlying problem. Also the audience had a diverse
background making it truly a contemporary translational
meeting.
On an organizational note, the registration fee for stu-
dents was greatly reduced in order to encourage students
to participate in the meeting. Given the still traditionally
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oriented curriculum of most university courses the meet-
ing served also an educational mission by providing an
object-lesson in interdisciplinary research.
Genomic medicine enables medicine on the
systems level
The welcome address of the conference was provided
by the Dean of the School of Medicine, Dentistry and
Biomedical Sciences, the newly elected President and
Vice-Chancellor of the Queen’s University Belfast, Profes-
sor Patrick Johnston. Professor Johnston emphasized the
general importance of computational & systems biology
approaches to understand causal disease mechanisms on
a genomic scale. Furthermore, he reminded at the begin-
nings of the conference that was initially funded by the
Department for Employment and Learning (DEL, UK)
to support the establishment of a Computational Biology
infrastructure in Belfast.
It is important to emphasize that Genomic Medicine
sets all boundary conditions that allows a systems analysis
of medicine. However, many approaches still do not uti-
lize available data up to their full potential but use them in
a traditional, reductionist manner, e.g., by neglecting cor-
relation structures among proteins or SNPs. Instead, the
talks presented in this session showed original and cre-
ative approaches for Genomic Medicine on the systems
level.
The first talk of the conference with the title ‘Modeling
Endocrine Resistance in Breast Cancer’, which was also
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the keynote lecture, was presented by Robert Clarke
(Biomedical Graduate Research Organization, Lombardi
Comprehensive Cancer Center, Georgetown University
Medical Center (USA)). The talk advocated the general
perspective that a systems biology approach is required
in order to integrate knowledge from cancer biology with
computational and mathematical methods. As a specific
case study, endocrine resistance in breast cancer was
discussed adopting a network medicine approach [2]. A
thought provoking conclusion from the presented analy-
sis was that endocrine resistance may not require many
new genes for its explanation, but just a few changes in the
usage of existing interactions among known genes.
Francesca Ciccarelli (Department of Experimental
Oncology, European Institute of Oncology, IFOM-IEO
Campus (Italy)) presented a talk about ‘Genomics and
Network Biology to Identify Systems level properties of
cancer genes’. In her talk common mutations in cancer
genes were discussed with the goal to identify driver genes
and novel therapeutic targets. As a result it was found
that cancer genes form interconnected hubs in the human
protein-protein interaction (PPI) network and are broadly
expressed, in particular in the cancer tissue where they
mutate. Furthermore, recessive cancer genes are old on
an evolutionary scale and form singleton hubs, whereas
dominant cancer genes are fairly recent present in the PPI
network as duplicated hubs [3].
Christos Hatzis (Yale Comprehensive Cancer Center,
Yale School of Medicine (USA)) gave a talk about ‘Com-
plexity and limits of predictability in breast cancer’.
Christos’ presentation started by emphasizing different
types of heterogeneity, e.g., inter-tumor and intra-tumor
heterogeneity, in breast cancer and methods for their
characterization. In the following, different breast can-
cer subtypes were studied quantitatively and basal-like
tumors were found to be more heterogeneous than HER2
or Luminal A and B. On a general note, it was sug-
gested to view the heterogeneity of tumors more as a
feature rather than a nuisance in order to exploit this
information.
Integrating data of different molecular and clinical
data sets
The important problem of data integration was addressed
by Sampsa Hautaniemi (Centre of Excellence in Cancer
Genetics, Faculty of Medicine, University of Helsinki
(Finland)) who gave a presentation with the title ‘Analysis
and integration of large-scale molecular and clinical data
in cancers’. Sampsa showed a study that integrated tran-
scriptional and clinical data of high-grade serous ovarian
cancer patients to identify molecular cause for platinum
resistance, which forms the standard chemotherapy. As a
result from this integrative analysis TR3 and its connec-
tion to signaling pathways were identified.
Also Andy Sims (Applied Bioinformatics of Cancer,
University of Edinburgh (UK)) presented a talk about the
integration of data with the title ‘Gene expression data
integration for breast cancer research’. However, in this
talk the integration of different data sets of the same type
were the central theme [4]. Specifically, the integration of
gene expression data from breast cancer were discussed
with a particular consideration of batch effects and the
reproducibility of results.
The following talk was a student presentation by Jaine
Blayney (Centre for Cancer Research and Cell Biology,
Queen’s University, Belfast, UK - now Lecturer at Univer-
sity of Ulster (UK)) taking about the ‘Determination of the
authenticity and lineage of cell lines using compositional
gene expression profiles’.
Network as a biomarker of the system
The first contribution discussing modern biomarker
approaches was given by Richard Kennedy (Center for
Cancer Research and Cell Biology, Queen’s University
Belfast (UK)) who gave a talk with the title ‘Discovery
and Validation of a Predictive Biomarker for Breast Can-
cer Chemotherapy’. The talk reported the identification
of a 44 gene signature biomarker corresponding to DNA
damage response deficiency (DDRD). Statistical as well
as experimental validations were presented and the bio-
logical basis of the DDRD 44 biomarker were investi-
gated leading to a connection with loss of the FA/BRCA
pathway [5,6].
Sol Efroni (The Mina and Everard Faculty of Life
Science, Bar Ilan University (Israel)) followed with a
talk entitled ‘The Network is a Biomarker in Cancer
Signatures’. Sol advocated the interesting hypothesis
that the networks underlying pathways could be used
as biomarkers. By studying gene expression data from
glioblastoma multiforme (GBM) and ovarian cancer the
p38/MAPKAP pathway and the PDGF signaling pathway
were reported to lead to a robust prognostic stratifica-
tion [7,8].
The next talk was again a student presentation given
by Fabio Liberante (Centre for Cancer Research and
Cell Biology, Queen’s University, Belfast, UK) with the
title ‘Identification of novel therapies in the treatment
of MDS/AML using a signature of disease development
and progression with the sscMap tool’. He reported his
recent work on the creation of a gene signature rep-
resenting the progression of disease state from healthy
condition to MDS then AML. Using the sscMap (Statis-
tically Significant Connections’ Map) tool [9], a number
of compounds were identified as having the potential to
reverse the disease state progression. His talk showcased
a success of applying a Quantitative Biology and Bioinfor-
matics approach to the identification of novel use for an
existing drug.
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Pharmacogenomics and drug identification
Ann Daly (Institute of Cellular Medicine, Newcastle
University Medical School (UK)) gave the first talk in the
Pharmacogenomics and drug identification session, with
the title ‘Use of GWAS and exome sequencing to iden-
tify genes relevant to drug-induced liver injury’. After
a background introduction of idiosyncratic adverse drug
reactions, she reported on the UK-wide study on drug-
induced liver injury usedDrug-induced liver injury (DILI),
for which she serves as a coordinator. The aim of the
study was to find genes predisposing to DILI using GWAS
(genome wide association study) and exome sequenc-
ing. Highly significant associations with particular HLA
genotypes were reported for idiosyncratic drug-induced
liver injury with several specific drugs, and the possible
underlying mechanisms were discussed. Her talk repre-
sented interesting showcases where Genomics has played
an important role in increasing our understanding of
individual risk for idiosyncratic drug-induced liver injury.
Munir Pirmohamed (Department of Molecular and
Clinical Pharmacology, The Wolfson Centre for Per-
sonalised Medicine, Institute of Translational Medicine,
University of Liverpool (UK)) followed on the theme on
adverse drug reactions by giving a talk with the title
‘Genomics of adverse drug reactions: the need for a multi-
functional approach’. He argued for the need to develop
multi-functional approaches to find solutions to prevent
Adverse Drug Reactions (ADRs), and described the efforts
of the international Serious Adverse Event Consortium
(iSAEC) in developing phenotype standardization for a
number of phenotypes in order to facilitate the transla-
tion of genomic predictors into clinical practice. He also
discussed the issue of different evidence standards that
are currently applied to non-genetic versus genetic tests.
Using examples of drug exposure and drug adverse reac-
tion, he highlighted the substantial differences between
the level of evidence required for pharmacogenetic tests
and that for non-genetic diagnostic tests. As these are
among the challenges holding back the translation of sys-
tems medicine, Munir Pirmohamed’s talk helped to raise
awareness of some existing bottleneck. He argued that a
level playing field for pharmacogenetic tests could help
accelerate the delivery of a more personalized medicine.
Through a video link, Aravind Subramanian (Broad
Institute of Harvard and MIT (USA)) gave a talk on
the LINCS (Library of Integrated Network-based Cellular
Signatures) project, which aims to create a network-based
understanding of biology by their systematic efforts to
generate over 1M gene expression profiles using chemical
or genetic perturbagens. Aravind described the develop-
ment of L1000 assay that has dramatically reduced the cost
of gene expression profiling. It was reported that the cur-
rent LINCS dataset contains over 1.2M gene expression
profiles, covering over 5k small molecule and 3k genetic
perturbagens. Data access was through multiple levels of
data matrices and cloud-compute beta has been released.
The utility of the LINCS dataset was demonstrated with
several examples of emerging scientific findings.
Benjamin Haibe-Kains (Bioinformatics and Compu-
tational Genomics Laboratory, Institut de Recherches
Cliniques de Montreal (Canada)), in his stimulating
talk ‘Are pharmacogenomic studies useful for developing
genomic predictors of drug response?’, reported his recent
work on comparing the datasets from several large-scale
pharmacogenomics studies [10]. The high-throughput
genomic data were well correlated, but he reported that
the measured pharmacological response to drug is poorly
correlated among these different studies. He suggested
that it was difficult to draw firm conclusions from the dis-
cordant pharmacological responses in the different stud-
ies. Furthermore, the validity and implications of using
IC50 and AUC as outcome measures to assess gene-drug
relationships was discussed. This study raised important
concerns and it remains to be seen how these problems
can be overcome.
Poster awards
The conference finished with awards for the best poster
presentations that were voted by the participants of
the conference. The first prize went to Fabio Liberante
(Center for Cancer Research and Cell Biology, Queen’s
University Belfast (UK)) with a poster on the same topic
that was selected for his oral presentation (see above).
The second prize went to Qing Wen (Center for Cancer
Research and Cell Biology, Queen’s University Belfast
(UK)) with a poster on ‘Gene signatures for connectivity
mapping to target disease phenotypes’, which describes
the development of a standardized procedure and proto-
col for creating disease gene signatures and their applica-
tions to cancer research. Both students received a book
voucher that was generously sponsored by Cambridge
University Press.
Conclusions
Due to the limited time frame of our conference the
contributed talks could not touch upon all aspects that
are of importance for Translational Medicine. For exam-
ple, Medical Bioinformatics [11] approaches for electronic
patient record data or Computational Physiology [12]
models for various biological systems, including drug
response, are currently of great importance. Neverthe-
less, an important message of the meeting that goes
beyond the individually contributed talks is that Genomic
Medicine does not only rely on computational approaches
for the number crunching of the data, but also as an
intellectual driving force. The latter relates, e.g., to the
experimental design of a study for ensuring the gen-
erated genomics data are actually usable for a systems
Emmert-Streib et al. Journal of Translational Medicine 2014, 12:26 Page 4 of 4
http://www.translational-medicine.com/content/12/1/26
approach rather than representing an accumulation of
massive amounts of reductionist data. Another example
is the usage of networks as a biomarker [13] and the
demonstration that such an abstract mathematical object
as a network can actually have a very practical medical
application.
Furthermore, the conference had a social agenda bring-
ing together experts from the dry and wet labs in a small
meeting, without parallel sessions, forcing them to talk
and interact with each other. Despite the general acknowl-
edgement that Genomic Medicine is an interdisciplinary
endeavor the communication between scientists from
these different worlds still needs improvement because
without a genuine understanding and appreciation of each
other the patients will not get the best possible treatment
that could be achieved collaboratively.
If the future of biology is dry in the sense of [14] remains
to be seen. However, it is unquestionable that computa-
tional approaches in Biomedicine are gaining more and
more importance in the near future, particularly in Trans-
lational Bioinformatics.
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